Imiprmaine vs. Sertraline in Panic Disorder: 24-Week Treatment Completers

References

• Lecrubier Y, Bakker A, Dunbar G, Judge R, Collaborative Paroxetine Panic Study Investigators: A comparison of parox-etine, clomipramine, and placebo in the treatment of panic disorder. Acta Psychiatry Scand 1997; 95:145–152
   PubMed Web of Science ®Google Scholar
• Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effects of citalopram in panic disorder. Br J Psychiatry 1997; 170:549–553
   PubMed Web of Science ®Google Scholar
• Bakish D, Hooper CL, Fiteau MJ, Charbonneau Y, Fraser G, Dixy LW, Thibaudeau C, Raine D: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with our without agoraphobia. Psy-chopharmacol Bull 1996; 32:135–141
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E. Sheehan ME Dunbar GC: Reliability and validity of the MINI international neuropsychiatric interview (M.I.N.I): according to the SCID-P. Eur Psychiatry 1997; 12:232–241
   Google Scholar
• Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Perel JM: Imipramine in panic disorder with agoraphobia: dose ranging and plasma level-response re-lationships. Am J Psychiatry 1995; 152:673–682
   PubMed Web of Science ®Google Scholar
• Londborg PD, Wolkow R, Smith WT, et at.: Sertraline in the treatment of panic disorder. Br .1 Psychiatry 1998; 173: 54–60
   Google Scholar
• Mavissakalian MR, Perel JM, Talbott-Green M, Sloan C: Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 1998; 43:848–854
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, PereLIM: Long-term maintenance and dis-continuation of imipramine therapy in panic disorder with ago-raphobia. Arch Gen Psychiatry 1999; 56:821–827
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Perel JM, deGroot C: Imipramine treat-ment of panic disorder with agoraphobia: The second time around. J Psychiatry Res 1993; 27:61–68
   Google Scholar
• Marks IM. Matthews AM: Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17:263–267
   Google Scholar
• Beck AT, War CH, Medelson M, Mock J. Erbaugh J: An in-ventory for measuring depression. Arch Gen Psychiatry 1961; 4:53–64
   Web of Science ®Google Scholar
• Peterson RA, Reiss S: Anxiety Sensitivity Index Revised Test Manual. Worthington, OH: International Diagnostics Ser-vices; 1992
   Google Scholar
• Montgomery SA: Selective norepinephrine reuptake inhibion: The unique role of reboxetine in depression, pp 688-691. In: Nelson JC, chair. Novel Antidepressant Strategies to Opti-mize Outcome (Academic Highlights). J Clin Psychiatry 2000; 61:686–696
   Google Scholar
• Versiani M, Cassana G, Perugi G, Benedetti A, ivlastalli L, Nardi A, Savino M: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002; 63:31–37
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Perel JM: The side effects burden of ex-tended imipramine treatment of panic disorder. J Clin Psy-chopharmacol 2002; 20:547–555
   Google Scholar
• Mavissakalian M, Perel J, Guo S: Specific side effects of long-term imipramine management of panic disorder. Clin Psy-chopharmacol 2002:22:155–161
   PubMed Web of Science ®Google Scholar
• Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Portera L, Miller NL, Adler D: Sexual function in chronically depressed patients treated with SSRI antidepressants: A pilot study. Am J Psychiatry 1997; 154:1757–1759
   PubMed Web of Science ®Google Scholar
• Labbate LA, Grimes JB, Arana GW: Serotonin reup-take antidepressant effects on sexual function in pa-tients with anxiety disorders. Biol Psychiatry 1998; 43:904–907
   Google Scholar
• Ware MR, Emmanuel NP, Johnson MR, Brawman-Mintzer O, Knapp R, Crawford-Harrison M, Lydiard RB: Self-reported sexual dysfunctions in anxiety disorder patients. Psychopharm-col Bull 1996; 32:530
   Web of Science ®Google Scholar